NCLT approves scheme of amalgamation of Cohance Lifesciences, Suven Pharmaceuticals

Suven Pharmaceuticals has obtained approval from National Company Law Tribunal (NCLT) for the Scheme of Amalgamation between Cohance Lifesciences and Suven Pharmaceuticals.

The amalgamation is expected to create a diversified CDMO platform with a technology-led focus across three high-growth verticals —antibody drug conjugates (ADCs), oligonucleotides, and small molecules.  The combined entity will operate as an integrated, end-to-end partner to global innovator pharmaceutical companies, further supported by strong capabilities in the Specialty CDMO and API+ business segments, a company statement said. 

“…This merger enhances our global capabilities, particularly in the growing and highly specialised areas of ADCs. With Cohance’s unique technological platform in ADC, we are well-positioned to become a $1 billion revenue company in next five years with higher CDMO contribution,’‘ Vivek Sharma, Executive Chairman, Suven Pharmaceuticals said. 

According to V. Prasada Raju, Managing Director, Suven Pharmaceuticals the approval of the merger marked a ‘significant milestone’ in the journey to build a differentiated and innovation-led CDMO platform from India. “The combined capabilities of Suven and Cohance position us strongly in high-growth areas such as ADCs, Oligonucleotides, and complex Small Molecules,” he added. 

According to the terms of the scheme, the merger will become effective from the opening business hours of the first day of the month immediately following the month in which all conditions specified under the scheme are fulfilled, including receipt of approval from the Department of Pharmaceuticals, where applicable. The effective date will be duly intimated to the stock exchanges for public disclosure in accordance with applicable regulations. As previously communicated, the cCompany expects to complete the amalgamation process by Q1 FY26.